Researchers from The University of Western Australia have developed a winning medicine formula that makes bad-tasting medicine taste nice, making it easier to treat sick children.
The UWA study published by the journal Anaesthesia tested 150 children and found that the majority of children who were given the new chocolate-tasting medicine would take it again, unlike the standard treatment, while they still experienced the same beneficial effects.
UWA Clinical Senior Lecturer Dr Sam Salman said the poor taste of many medicines, such as Midazolam, a sedative used prior to surgery, presented a real difficulty in effectively treating children.
A lens just a billionth of a metre thick could transform phone cameras. Swinburne researchers have created ultra-thin lenses that cap an optical fibre, and can produce images with the quality and sharpness of much larger glass lenses.
Polymers are being used for non-stick coatings, anti-fouling technology, precision drug delivery, medical diagnosis, imaging, and many other applications.
Associate Professor Cyrille Boyer’s ideas are built on the revolutionary RAFT techniques (a technique to precisely control how small molecules are linked together to form large polymer chains) for which Professor David Solomon and Dr Ezio Rizzardo received the 2011 Prime Minister’s Prize for Science. His latest technology uses light and chlorophyll to catalyse the production of polymers.
A new diagnostic system used to detect cancer cells in small blood samples could next be turned towards filtering a patient’s entire system to remove those dangerous cells – like a dialysis machine for cancer – says an Australian researcher who helped develop the system.
The technique was developed for cancer diagnosis, and is capable of detecting (and removing) a tiny handful of cancer-spreading cells from amongst the billions of healthy cells in a small blood sample.
The revolutionary system, which works to diagnose cancer at a tenth of the cost of competing technologies, is now in clinical trials in the US, UK, Singapore and Australia, and is in the process of being commercialised by Clearbridge BioMedics PteLtd in Singapore.